FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3210990120> ?p ?o ?g. }

• W3210990120 endingPage "e597" @default.
• W3210990120 startingPage "e596" @default.
• W3210990120 abstract "Patients with high-grade gliomas (HGG) progress despite multimodality therapy. Hypofractionated stereotactic re-irradiation therapy (HFSRT) has been used with promising efficacy as a salvage treatment in the setting of recurrent HGG (rHGG). We recently completed a phase I study combining HFSRT with concurrent pembrolizumab and bevacizumab (Bev) for patients with rHGG (NCT02313272). The main objective of this study is to identify patterns of failure in the above regimen.Data from 32 patients enrolled in the phase I trial from June 2015 to January 2018 were reviewed. Patient characteristics, time to progression, and treatment outcomes were evaluated. Brain MRIs were taken at baseline, and every 6 to 8 weeks until progression. T1 post-contrast and T2- FLAIR images at baseline and at progression were imported into commercial software and the extent of hyperintensity was contoured by a single physician and reviewed by a second physician. An automated algorithm was used to compare the volumetric similarities between the pre- and post-treatment structures. This algorithm used Dice similarity coefficient (DSC), a statistical validating index for evaluating reproducibility and spatial overlap accuracy in the MRI image segmentation. A DSC value of 0.3 or greater indicated significant spatial overlap accuracy. Pearson's single and two-tailed tests were used to identify correlation between time to progression and volumetric parameters.The median age of patients at re-irradiation was 56 years (22-68).24 patients had Bev naïve tumor. The median radiation dose was 35 Gy in 5 fractions (25-40). The median progression free survival was 7.92 months (95% CI:6.31-12.45). A total of 22 (68%) patients with radiological progression were included for this analysis. Considerable similarities were observed (11/22) between the pretreatment T2- FLAIR and the post-treatment T1 contrast: with a median DSC of 0.31(range 0.05-0.6) and pre-treatment T2-FLAIR and post-treatment T2-FLAIR; DSC 0.66 (range 0.15-0.7). The median DSC value comparing pre- and post-treatment T1 contrast volumes were 0.24 (range 0-0.5). These findings suggest that recurrence or progression occurred in the pretreatment T2-FLAIR region outside the pre-treatment post-contrast T1 region. A positive correlation between time to progression with maximum dose received by pre-treatment (P = 0.02) and post-treatment T2-FLAIR (P = 0.02) volumes was observed.Our analysis of a prospective trial of HSFRT with concurrent pembrolizumab and bevacizumab showed recurrences occurred outside the radiation field (i.e., region of T1post contrast abnormality). Recurrences predominantly occurred in the pre-treatment T2-FLAIR region. Including T2-FLAIR region in the pre-treatment GTV contours may be needed in achieving optimal local control.R. Padmanabhan: None. G.G. Zhang: None. D.E. Oliver: None. J. Graham: None. D. Grass: None. S. Sahebjam: Research Grant; Merck, Bristol Myers Squibb and Brooklyn Immuno Therapeutics. Advisory Board; Merck, Boehringer Ingelheim. Travel Expenses; Eli Lilly. H.M. Yu: Honoraria; UpToDate. Speaker's Bureau; BrainLab. Advisory Board; Novocure, AbbVie." @default.
• W3210990120 created "2021-11-08" @default.
• W3210990120 creator A5001880989 @default.
• W3210990120 creator A5003748444 @default.
• W3210990120 creator A5022474990 @default.
• W3210990120 creator A5025331599 @default.
• W3210990120 creator A5026380696 @default.
• W3210990120 creator A5034442780 @default.
• W3210990120 creator A5057791644 @default.
• W3210990120 date "2021-11-01" @default.
• W3210990120 modified "2023-09-25" @default.
• W3210990120 title "Patterns of Failure in Patients With Recurrent High-Grade Glioma Treated With Hypofractionated Stereotactic Re-Irradiation, Pembrolizumab, and Bevacizumab" @default.
• W3210990120 doi "https://doi.org/10.1016/j.ijrobp.2021.07.1595" @default.
• W3210990120 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34701835" @default.
• W3210990120 hasPublicationYear "2021" @default.
• W3210990120 type Work @default.
• W3210990120 sameAs 3210990120 @default.
• W3210990120 citedByCount "0" @default.
• W3210990120 crossrefType "journal-article" @default.
• W3210990120 hasAuthorship W3210990120A5001880989 @default.
• W3210990120 hasAuthorship W3210990120A5003748444 @default.
• W3210990120 hasAuthorship W3210990120A5022474990 @default.
• W3210990120 hasAuthorship W3210990120A5025331599 @default.
• W3210990120 hasAuthorship W3210990120A5026380696 @default.
• W3210990120 hasAuthorship W3210990120A5034442780 @default.
• W3210990120 hasAuthorship W3210990120A5057791644 @default.
• W3210990120 hasBestOaLocation W32109901201 @default.
• W3210990120 hasConcept C101070640 @default.
• W3210990120 hasConcept C121608353 @default.
• W3210990120 hasConcept C126322002 @default.
• W3210990120 hasConcept C126838900 @default.
• W3210990120 hasConcept C143409427 @default.
• W3210990120 hasConcept C143998085 @default.
• W3210990120 hasConcept C146638467 @default.
• W3210990120 hasConcept C2776694085 @default.
• W3210990120 hasConcept C2777701055 @default.
• W3210990120 hasConcept C2777802072 @default.
• W3210990120 hasConcept C2778227246 @default.
• W3210990120 hasConcept C2780057760 @default.
• W3210990120 hasConcept C2780387249 @default.
• W3210990120 hasConcept C2780739268 @default.
• W3210990120 hasConcept C2989005 @default.
• W3210990120 hasConcept C3019894029 @default.
• W3210990120 hasConcept C502942594 @default.
• W3210990120 hasConcept C509974204 @default.
• W3210990120 hasConcept C71924100 @default.
• W3210990120 hasConceptScore W3210990120C101070640 @default.
• W3210990120 hasConceptScore W3210990120C121608353 @default.
• W3210990120 hasConceptScore W3210990120C126322002 @default.
• W3210990120 hasConceptScore W3210990120C126838900 @default.
• W3210990120 hasConceptScore W3210990120C143409427 @default.
• W3210990120 hasConceptScore W3210990120C143998085 @default.
• W3210990120 hasConceptScore W3210990120C146638467 @default.
• W3210990120 hasConceptScore W3210990120C2776694085 @default.
• W3210990120 hasConceptScore W3210990120C2777701055 @default.
• W3210990120 hasConceptScore W3210990120C2777802072 @default.
• W3210990120 hasConceptScore W3210990120C2778227246 @default.
• W3210990120 hasConceptScore W3210990120C2780057760 @default.
• W3210990120 hasConceptScore W3210990120C2780387249 @default.
• W3210990120 hasConceptScore W3210990120C2780739268 @default.
• W3210990120 hasConceptScore W3210990120C2989005 @default.
• W3210990120 hasConceptScore W3210990120C3019894029 @default.
• W3210990120 hasConceptScore W3210990120C502942594 @default.
• W3210990120 hasConceptScore W3210990120C509974204 @default.
• W3210990120 hasConceptScore W3210990120C71924100 @default.
• W3210990120 hasIssue "3" @default.
• W3210990120 hasLocation W32109901201 @default.
• W3210990120 hasLocation W32109901202 @default.
• W3210990120 hasOpenAccess W3210990120 @default.
• W3210990120 hasPrimaryLocation W32109901201 @default.
• W3210990120 hasRelatedWork W1963572951 @default.
• W3210990120 hasRelatedWork W1982514235 @default.
• W3210990120 hasRelatedWork W2025724318 @default.
• W3210990120 hasRelatedWork W2047244875 @default.
• W3210990120 hasRelatedWork W2137249880 @default.
• W3210990120 hasRelatedWork W2166534891 @default.
• W3210990120 hasRelatedWork W2260849462 @default.
• W3210990120 hasRelatedWork W2928859004 @default.
• W3210990120 hasRelatedWork W4317566941 @default.
• W3210990120 hasRelatedWork W2903625709 @default.
• W3210990120 hasVolume "111" @default.
• W3210990120 isParatext "false" @default.
• W3210990120 isRetracted "false" @default.
• W3210990120 magId "3210990120" @default.
• W3210990120 workType "article" @default.